Absci Corporation Common Stock (ABSI)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at Absci at the close on 2026-10-13, I see a clinical-stage biopharmaceutical company with a $1.6B market capitalization and a $9.10 share price. It develops antibody therapeutics, with programs such as ABS-101 in Phase 1 for inflammatory bowel disease and ABS-201 in Phase 1/2a for androgenic alopecia. But quality, for me, starts with durable earnings, and there are none. In fiscal 2025, Absci reported revenue of $2.8M and a net loss of $115.2M. In fiscal 2024, revenue was $4.5M and net loss $103.1M; in fiscal 2023, revenue was $5.7M and net loss $110.6M. The latest fiscal Q2 2026, the quarter ended 2026-06-30, showed revenue of $318,000 and a net loss of $33.2M, with diluted EPS of -$0.21. Revenue is not growing; it is shrinking. The moat is unproven because no commercial product is described here, and value depends on clinical trials and collaborations. Financial health has one positive: debt is tiny, with D/E 0.02, and the FairStock calculation shows an Altman Z-Score of 37.97. But trailing free cash flow is -$109.0M, a -7.0% FCF yield, and ROE is -57.72%. FairStock's Piotroski F-Score is 5/9, and its FairStock Score is 30/100. At that close, FairStock's calculations show P/B 6.32, P/E -11.52, and ROCE -34.09%. The company has lost money each of the last four years, so the computed Lynch category is none. This is not a Graham bargain; it is a long-duration clinical bet with a high beta of 2.44. I would need far more evidence of a protective franchise and a path to cash generation before calling the price attractive.

In plain English: Absci is a healthcare company testing new antibody medicines, mostly in early-stage human trials. The business looks weak because it has almost no revenue, loses tens of millions each quarter, and has not made a profit in the last four years. At $9.10, the price looks expensive compared with its tiny sales and lack of earnings, so it depends heavily on future trial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer